NRX Pharmaceuticals (NRXP) News
NASDAQ: NRXPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NRXP news summary
We found 12 recent headlines mentioning NRX Pharmaceuticals (NRXP): 5 in the past week and 10 in the past 30 days, most often from GlobeNewswire, Nasdaq. NRXP is making an outsized move today, down 15.69% at $2.15, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Biotech Stocks On The Rise - AKAN +88%, CUE +49%, ADAG +24%, ANTX +23%, NRXP +10%", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest NRX Pharmaceuticals headlines
- Biotech Stocks On The Rise - AKAN +88%, CUE +49%, ADAG +24%, ANTX +23%, NRXP +10%(RTTNews) - Shares of several biotech and healthcare companies moved higher amid clinical updates, quarterly results and increased trading activity. Akanda and Adagene rallied without fresh…NasdaqADAG, AKAN, ANTX, CUE
- NRx (NRXP) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- NRx Reports Narrower Q3 Loss, Highlights Commercial Launch And Expanding Ketamine Pipeline; Stock Up(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP) reported third-quarter 2026 results and outlined its transition from a development-stage biotechnology company to a commercial-stage business following…NasdaqNRXP, ET
- NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateFDA approved the Company’s first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales forceGlobeNewswire
- NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue EstimatesNRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +82.76% and -14.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the…NasdaqNRXP, A
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate UpdateWILMINGTON, Del., Nov. 12, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target…GlobeNewswire
- NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running ShortageWILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target…GlobeNewswire
- NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal DateWILMINGTON, Del., Oct. 30, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target…GlobeNewswire
- NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free KetamineCompany to issue press release before market open; conference call to follow at 8:30 a.m. ET Company to issue press release before market open; conference call to follow at 8:30 a.m. ETGlobeNewswire
- Biotech Stocks Facing FDA Decision In November 2026(RTTNews) - The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.NasdaqAGIO, BBIO, CAPR, COGT
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free KetamineWILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its…GlobeNewswire
- NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free KetamineWILMINGTON, Del., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a biopharmaceutical company that focuses on neuroplastic therapies for…GlobeNewswire